New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
11:36 EDTJAZZCANbridge Life Sciences and EUSA Pharma form agreement to commercialize Caphosol
CANbridge Life Sciences has entered into an exclusive partnership with EUSA Pharma, a Jazz Pharmaceuticals company, to commercialize CaphosolŪ in China. Under the terms of the agreement, CANbridge obtains exclusive rights to commercialize Caphosol in China, where over 3.5M new cancer cases are diagnosed each year, and there is little in the way of a standard adjunct therapy to treat oral mucositis. Caphosol is a prescription medical device, approved in the United States and European Union, designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
09:08 EDTJAZZJazz Pharmaceuticals reports data from Phase 3 pivotal study of defibrotide
Jazz Pharmaceuticals announced that data from the phase 3 pivotal study of defibrotide were published online in BLOOD, the Journal of the American Society of Hematology, or ASH. The data demonstrated that defibrotide use in patients with hepatic veno-occlusive, or VOD, also known as sinusoidal obstruction syndrome, with multi-organ failure post-hematopoietic stem-cell transplantation was associated with a statistically significant improvement in Day +100 survival and in rate of complete response by Day +100, compared with rigorously selected historical controls.
January 29, 2016
06:55 EDTJAZZ2016 could be pivotal year for Jazz, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert says 2016 could be a pivotal year for Jazz Pharmaceuticals. The analyst sees several potential catalysts for the shares, including potentially greater certainty on Xyrem duration via a patent settlement or a win in court, FDA approval of defibrotide and acquisitions supported by the company's under-leveraged balance sheet. Gilbert keeps a Buy rating on Jazz with a $167 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use